Have Insiders Sold Swedish Orphan Biovitrum Shares Recently?
Some Swedish Orphan Biovitrum AB (publ) (STO:SOBI) shareholders may be a little concerned to see that the CEO & President, Guido Oelkers, recently sold a substantial kr37m worth of stock at a price of kr467 per share. That's a big disposal, and it decreased their holding size by 12%, which is notable but not too bad.
Swedish Orphan Biovitrum Insider Transactions Over The Last Year
Notably, that recent sale by CEO & President Guido Oelkers was not the only time they sold Swedish Orphan Biovitrum shares this year. They previously made an even bigger sale of -kr92m worth of shares at a price of kr464 per share. So what is clear is that an insider saw fit to sell at around the current price of kr446. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
Over the last year, we can see that insiders have bought 69.19k shares worth kr31m. But they sold 1.46m shares for kr561m. Over the last year we saw more insider selling of Swedish Orphan Biovitrum shares, than buying. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
See our latest analysis for Swedish Orphan Biovitrum
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
Insider Ownership Of Swedish Orphan Biovitrum
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Insiders own 0.3% of Swedish Orphan Biovitrum shares, worth about kr537m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Do The Swedish Orphan Biovitrum Insider Transactions Indicate?
The stark truth for Swedish Orphan Biovitrum is that there has been more insider selling than insider buying in the last three months. Zooming out, the longer term picture doesn't give us much comfort. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 3 warning signs for Swedish Orphan Biovitrum and we suggest you have a look.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.